Core Viewpoint - Lexeo Therapeutics, Inc. is actively participating in the Leerink Global Healthcare Conference, highlighting its commitment to advancing genetic medicine for cardiovascular diseases [1]. Company Overview - Lexeo Therapeutics is a clinical stage genetic medicine company based in New York City, focused on innovative treatments for cardiovascular diseases [3]. - The company is developing a portfolio of therapeutic candidates targeting genetic causes of conditions, including LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for plakophilin-2 arrhythmogenic cardiomyopathy [3]. Event Details - The fireside chat at the Leerink Global Healthcare Conference is scheduled for March 10, 2026, at 10:00 a.m. ET in Miami, FL [1]. - The event will be available for live webcast and a replay will be accessible on the company's website afterward [2].
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference